FacebookTwitterGoogle+RedditEmail

Do You Know Where Your Child Is?

2009 will be remembered for the two biggest settlements in US history: Eli Lilly agreed to pay $1.42 billion for mismarketing the antipsychotic Zyprexa and Pfizer agreed to pay $2.3 billion for fraud associated with the antipsychotic Geodon, withdrawn painkiller Bextra, the seizure drug Lyrica and the antibiotic Zyvox.

The drug industry will continue to dole out such payouts writes Bloomberg’s David Evans, and consider them a slap on the wrist until prosecutors and judges “use the ultimate sanction, a felony conviction that would render a company’s drugs ineligible for reimbursement by state health programs and federal Medicare.”

Nor did the mismarketing and fraud only enrich drug companies and loot Medicaid and Medicare tax dollars.

Doctor have also cleaned up like Chicago psychiatrist Michael Reinstein who received $500,000 to promote a drug that Medicaid records say he prescribed 41,000 times according to Chicago Tribune and Propublico, figures Reinstein disputes.

And Miami psychiatrist Fernando Mendez-Villamil who wrote 97,000 psychoactive prescriptions for Medicaid patients over 18 months says the Miami Herald –153 prescriptions a day. His prescribathon even drew a letter from Sen. Charles Grassley, ranking member of the Senate Finance Committee.

It’s no secret that the atypical antipsychotics Reinstein and Mendez-Villamil prescribed, which include Seroquel, Zyprexa and Abilify, are used to “manage” agitated patients in nursing homes though their labels say, “Elderly patients with dementia-related psychosis” are at “an increased risk of death.” Three unreported deaths even occurred under Reinstein’s care says Illinois Department of Public Health spokeswoman Melaney Arnold.

It’s no secret they’re an institutional goldmine for the drug industry who exacted $5 million for one year of atypical drugs at Western State mental hospital in Tacoma, WA according to the News-Tribune. Many states have sued over the cost of atypicals, especially the cost of treating the diabetes and metabolic disorders they cause, which has decimated Medicaid budgets.

What is a secret is why the FDA would give the drug industry the Christmas present of approving Seroquel and Zyprexa for children in early December and hence, Medicaid reimbursement even as its own Division of Pharmacovigilance (DPV) reported a “a direct association between adverse metabolic effects of treatment with atypical antipsychotics” and children. A hypothesis the DPV report says is “provocative” and requires “robust” followup.

The FDA ignored the concurrent report and approved the drugs–Seroquel Immediate Release tablets to treat schizophrenia in adolescents ages 13-17 and bipolar mania in children and adolescents ages 10-17; Zyprexa to treat schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17– even as studies continue to link them to Diabetes mellitus, hyperglycemia, diabetic ketoacidosis, hyperlipidemia, galactorrhea and hyperprolactinemia in children.

The FDA’s own Adverse Event Reporting System database “contains thousands of domestic reports describing extrapyramidal symptoms and metabolic effects reported in association with these agents,” says the DPV report in addition to the existence of “a number of lawsuits against olanzapine [Zyprexa] and quetiapine [Seroquel] involving metabolic effects.”

Fifty-one medical journal articles since 1999 link Zyprexa alone with diabetic ketoacidosis, an acute metabolic condition which can rapidly escalate to cerebral edema and coma. Four articles recount sudden death in patients who had no personal or family history of diabetes mellitus and normal levels of the drug in their system.

In fact June FDA Psychopharmacological Advisory Committee hearings about approving Seroquel and Zyprexa for children itemized those exact side effects. AstraZeneca physician Liza O’Dowd did a valiant job of assuring committee members that weight, glucose and prolactin elevation side effects of Seroquel could be “controlled and monitored” in patients and that they “didn’t lead to discontinuation of the study.” (Hopefully not when the study lasted weeks).

But Christopher B. Granger, MD, Director of Duke University Medical Center’s Cardiac Care confessed to “real discomfort” approving drugs which “generat[e] metabolic syndrome in adolescents in a very short period of time” for “indefinite use” on the basis of three or six week trials. “Hopefully we’re not exposing someone for decades,” he said. Colleague, Edward L.C. Pritchett, MD with Duke’s Cardiology and Clinical Pharmacology agreed.

The stealth approvals of new uses and insurance reimbursement for atypical antipsychotics is the FDA’s gift to the drug industry. Call it their Secret Santa.

MARTHA ROSENBERG can be reached at: martharosenberg@sbcglobal.net

 

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

September 25, 2018
Kenneth Surin
Fact-Finding Labour’s “Anti-Semitism” Crisis
Charles Pierson
Destroying Yemen as Humanely as Possible
James Rothenberg
Why Not Socialism?
Patrick Cockburn
How Putin Came Out on Top in Syria
John Grant
“Awesome Uncontrollable Male Passion” Meets Its Match
Guy Horton
Burma: Complicity With Evil?
Steve Stallone
Jujitsu Comms
William Blum
Bombing Libya: the Origins of Europe’s Immigration Crisis
John Feffer
There’s a New Crash Coming
Martha Pskowski
“The Emergency Isn’t Over”: the Homeless Commemorate a Year Since the Mexico City Earthquake
Fred Baumgarten
Ten Ways of Looking at Civility
Dean Baker
The Great Financial Crisis: Bernanke and the Bubble
Binoy Kampmark
Parasitic and Irrelevant: The University Vice Chancellor
September 24, 2018
Jonathan Cook
Hiding in Plain Sight: Why We Cannot See the System Destroying Us
Gary Leupp
All the Good News (Ignored by the Trump-Obsessed Media)
Robert Fisk
I Don’t See How a Palestinian State Can Ever Happen
Barry Brown
Pot as Political Speech
Lara Merling
Puerto Rico’s Colonial Legacy and Its Continuing Economic Troubles
Patrick Cockburn
Iraq’s Prime Ministers Come and Go, But the Stalemate Remains
William Blum
The New Iraq WMD: Russian Interference in US Elections
Julian Vigo
The UK’s Snoopers’ Charter Has Been Dealt a Serious Blow
Joseph Matten
Why Did Global Economic Performance Deteriorate in the 1970s?
Zhivko Illeieff
The Millennial Label: Distinguishing Facts from Fiction
Thomas Hon Wing Polin – Gerry Brown
Xinjiang : The New Great Game
Binoy Kampmark
Casting Kavanaugh: The Trump Supreme Court Drama
Max Wilbert
Blue Angels: the Naked Face of Empire
Weekend Edition
September 21, 2018
Friday - Sunday
Alexandra Isfahani-Hammond
Hurricane Florence and 9.7 Million Pigs
Andrew Levine
Israel’s Anti-Semitism Smear Campaign
Paul Street
Laquan McDonald is Being Tried for His Own Racist Murder
Brad Evans
What Does It Mean to Celebrate International Peace Day?
Nick Pemberton
With or Without Kavanaugh, The United States Is Anti-Choice
Jim Kavanagh
“Taxpayer Money” Threatens Medicare-for-All (And Every Other Social Program)
Jonathan Cook
Palestine: The Testbed for Trump’s Plan to Tear up the Rules-Based International Order
Jeffrey St. Clair
Roaming Charges: the Chickenhawks Have Finally Come Back Home to Roost!
David Rosen
As the Capitalist World Turns: From Empire to Imperialism to Globalization?
Jonah Raskin
Green Capitalism Rears Its Head at Global Climate Action Summit
James Munson
On Climate, the Centrists are the Deplorables
Robert Hunziker
Is Paris 2015 Already Underwater?
Arshad Khan
Will There Ever be Justice for Rohingya Muslims?
Jill Richardson
Why Women Don’t Report Sexual Assault
Dave Clennon
A Victory for Historical Accuracy and the Peace Movement: Not One Emmy for Ken Burns and “The Vietnam War”
W. T. Whitney
US Harasses Cuba Amid Mysterious Circumstances
Nathan Kalman-Lamb
Things That Make Sports Fans Uncomfortable
George Capaccio
Iran: “Snapping Back” Sanctions and the Threat of War
Kenneth Surin
Brexit is Coming, But Which Will It Be?
FacebookTwitterGoogle+RedditEmail